Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte | 10 studies | 45% ± 19% | |
astrocyte | 6 studies | 27% ± 11% | |
microglial cell | 4 studies | 27% ± 11% | |
epithelial cell | 3 studies | 26% ± 3% | |
oligodendrocyte precursor cell | 3 studies | 26% ± 10% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 5 studies | 35% ± 18% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1944.52 | 1443 / 1445 | 100% | 11.08 | 183 / 183 |
intestine | 100% | 1951.35 | 966 / 966 | 99% | 10.96 | 524 / 527 |
stomach | 100% | 1182.01 | 358 / 359 | 100% | 10.16 | 285 / 286 |
prostate | 100% | 2058.76 | 245 / 245 | 99% | 12.94 | 497 / 502 |
lung | 100% | 1560.62 | 577 / 578 | 99% | 9.03 | 1145 / 1155 |
brain | 100% | 1784.11 | 2630 / 2642 | 99% | 9.99 | 699 / 705 |
breast | 100% | 1129.56 | 459 / 459 | 97% | 8.25 | 1088 / 1118 |
thymus | 100% | 3717.31 | 653 / 653 | 97% | 12.96 | 588 / 605 |
pancreas | 99% | 1065.55 | 326 / 328 | 98% | 8.15 | 174 / 178 |
bladder | 100% | 1933.14 | 21 / 21 | 96% | 8.45 | 485 / 504 |
liver | 100% | 2088.12 | 226 / 226 | 92% | 9.00 | 373 / 406 |
kidney | 100% | 1924.90 | 89 / 89 | 91% | 6.04 | 823 / 901 |
uterus | 100% | 1287.99 | 170 / 170 | 91% | 6.45 | 417 / 459 |
ovary | 99% | 926.01 | 178 / 180 | 85% | 3.44 | 366 / 430 |
skin | 100% | 1074.96 | 1804 / 1809 | 77% | 3.60 | 363 / 472 |
adrenal gland | 98% | 930.20 | 252 / 258 | 70% | 2.64 | 162 / 230 |
adipose | 100% | 1095.04 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 1519.99 | 1335 / 1335 | 0% | 0 | 0 / 0 |
spleen | 100% | 1424.84 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 2.49 | 1 / 1 |
peripheral blood | 100% | 2873.78 | 925 / 929 | 0% | 0 | 0 / 0 |
muscle | 99% | 1359.75 | 792 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 96% | 8.34 | 43 / 45 |
heart | 87% | 636.40 | 751 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 76% | 6.79 | 22 / 29 |
eye | 0% | 0 | 0 / 0 | 29% | 0.75 | 23 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_2001271 | Biological process | negative regulation of cysteine-type endopeptidase activity involved in execution phase of apoptosis |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_0070936 | Biological process | protein K48-linked ubiquitination |
GO_1901796 | Biological process | regulation of signal transduction by p53 class mediator |
GO_0006915 | Biological process | apoptotic process |
GO_1902042 | Biological process | negative regulation of extrinsic apoptotic signaling pathway via death domain receptors |
GO_0010762 | Biological process | regulation of fibroblast migration |
GO_0010804 | Biological process | negative regulation of tumor necrosis factor-mediated signaling pathway |
GO_0032006 | Biological process | regulation of TOR signaling |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_1901797 | Biological process | negative regulation of signal transduction by p53 class mediator |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0005764 | Cellular component | lysosome |
GO_0055038 | Cellular component | recycling endosome membrane |
GO_0005654 | Cellular component | nucleoplasm |
GO_0000139 | Cellular component | Golgi membrane |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0010008 | Cellular component | endosome membrane |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0019901 | Molecular function | protein kinase binding |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0002020 | Molecular function | protease binding |
GO_0002039 | Molecular function | p53 binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0005515 | Molecular function | protein binding |
Gene name | RFFL |
Protein name | E3 ubiquitin-protein ligase rififylin (EC 2.3.2.27) (Caspase regulator CARP2) (Caspases-8 and -10-associated RING finger protein 2) (CARP-2) (FYVE-RING finger protein Sakura) (Fring) (RING finger and FYVE-like domain-containing protein 1) (RING finger protein 189) (RING finger protein 34-like) (RING-type E3 ubiquitin transferase rififylin) Ring finger and FYVE like domain containing E3 ubiquitin protein ligase |
Synonyms | RNF189 RNF34L |
Description | FUNCTION: E3 ubiquitin-protein ligase that regulates several biological processes through the ubiquitin-mediated proteasomal degradation of various target proteins. Mediates 'Lys-48'-linked polyubiquitination of PRR5L and its subsequent proteasomal degradation thereby indirectly regulating cell migration through the mTORC2 complex. Ubiquitinates the caspases CASP8 and CASP10, promoting their proteasomal degradation, to negatively regulate cell death downstream of death domain receptors in the extrinsic pathway of apoptosis. Negatively regulates the tumor necrosis factor-mediated signaling pathway through targeting of RIPK1 to ubiquitin-mediated proteasomal degradation. Negatively regulates p53/TP53 through its direct ubiquitination and targeting to proteasomal degradation. Indirectly, may also negatively regulate p53/TP53 through ubiquitination and degradation of SFN. May also play a role in endocytic recycling. . |
Accessions | ENST00000315249.11 [Q8WZ73-1] ENST00000447669.6 [Q8WZ73-1] Q8WZ73 J3KSI3 ENST00000581265.1 ENST00000584655.5 [Q8WZ73-3] J3KSU7 ENST00000394597.7 [Q8WZ73-1] ENST00000581039.1 J3QR17 C9JE27 ENST00000415395.6 [Q8WZ73-1] ENST00000413582.6 [Q8WZ73-2] ENST00000582308.1 ENST00000414419.6 |